Lynx.MD, a provider of a comprehensive medical data intelligence platform, has launched a massive real-world gastroenterology (GI) data repository. This repository includes both structured and unstructured data assets and has been developed through strategic partnerships with organizations like Gastro Health and Allied Digestive. The platform is designed to support Bio Pharma and Medtech companies in developing, testing, and validating GI-related therapies by leveraging the insights from these datasets.
The Lynx.MD platform’s dynamic GI data library, which is expanding daily, encompasses a wide range of data, including:
- Over 12 million patients
- More than 60 million patient encounters
- Over 100 million prescription and medication records
- 90 million+ clinical notes
- 1 million+ colonoscopies imaging and notes
This extensive data collection aims to address pervasive gastroenterological diseases such as Nonalcoholic Fatty Liver Disease (NAFLD), Gastroesophageal Reflux Disease (GERD), Irritable Bowel Syndrome (IBS), Inflammatory Bowel Disease (IBD), and Colon Cancer. These conditions significantly impact global health, with the World Health Organization (WHO) reporting that approximately 2 billion people annually experience some form of GI disease.
Lynx.MD’s data-driven solutions are positioned to tackle these challenges head-on. The repository’s depth offers a unique advantage for those seeking to advance research and AI development, validate therapies, and accelerate improvements in care for gastroenterological patients. Lynx MD is committed to transforming traditional data access control models by making complex real-world data available for innovation within a secure, dedicated cloud environment that protects patient privacy.